Thesis

Foghorn Therapeutics is the only public company systematically drugging chromatin regulatory complexes — the SWI/SNF protein machinery that's mutated in 25% of all cancers. The FY2025 10-K reveals a concrete pipeline catalyst wave: four IND filings planned over the next two years, each targeting proteins where no other company has a development program. The stock trades at $4.92, 27% below where BVF Partners, Deerfield, and Flagship Pioneering paid to get in two months ago. The market is pricing a single-asset pre-revenue biotech with cash anxiety. The 10-K, competitive landscape analysis, and Lilly's trial design tell a different story.

What the 10-K Shows

The most important line in FHTX's annual filing isn't in the financials. It's in the pipeline discussion: "We believe we have the potential to file four INDs over the next two years."

Four named selective degrader programs, all first-in-class:

1. SMARCA2 degrader — Lilly-partnered. Alongside FHD-909 (the SMARCA2 inhibitor already in Phase 1). Degrades the protein rather than just blocking its enzymatic function.
2. CBP degrader (FHT-CBPd-9) — Targets EP300-mutated/CBP-dependent cancers. CDX data showing tumor regression in gastric and bladder models. Addressable population: 500K+ US annual incidence across endometrial, cervical, ovarian, bladder, colorectal, and ER+ breast cancers. Already in dose range finding tox studies as of Q4 2025.
3. EP300 degrader (FHT-EP300d-32) — Targets CBP-mutated/EP300-dependent cancers: multiple myeloma, DLBCL, AML, MDS. Outperforms enzalutamide in AR+ prostate preclinical model. IND-enabling studies tracking to 2026.
4. ARID1B degrader — Targets ARID1A-mutated cancers (endometrial, gastric, bladder, NSCLC). ARID1B has no enzymatic activity — it's a scaffolding protein, making it undruggable by conventional approaches. Foghorn claims to have solved this with bifunctional degraders. Earliest-stage of the four.

The compound designations (FHT- prefix) and tox study timelines mean candidate selection is complete for at least the first two programs. This isn't aspirational pipeline talk. The CBP degrader is in tox NOW.

On the financials: Cash and securities totaled $158.9M at year-end, lower than the $243.8M at end of 2024. The company burned $86.1M in FY2025, down 14% from $100.4M the prior year — driven partly by discontinuing FHD-286 (saved $10.2M/yr) and partly by Lilly cost-sharing on FHD-909. Collaboration revenue grew 37% to $30.9M as the $300M Lilly upfront continues to be recognized ($249.2M still deferred). No going concern. Clean audit.

What the 10-K doesn't capture: a $50M registered direct closed in January 2026 at $6.71/share — a 30% premium to market — with warrants struck at $13.42 and $20.13. The buyers were BVF Partners, Deerfield Management, and Flagship Pioneering (Foghorn's founding venture firm). This extends cash runway to approximately H1 2028, covering the entire four-IND catalyst wave.

The Competitive Void

We searched the competitive landscape exhaustively: SEC filings of every major TPD company (Arvinas, Kymera, C4 Therapeutics, Nurix), 5,466 earnings transcripts, and web/academic literature.

SMARCA2: Foghorn's only clinical competitor, Prelude Therapeutics, paused both SMARCA2 programs on November 4, 2025. Not for safety or regulatory reasons — capital constraints forced a strategic pivot to a JAK2 program with Incyte. Prelude had $77.3M cash and runway only to Q2 2026. Before pausing, Prelude's PRT3789 generated 3 confirmed partial responses in 65 patients and PRT7732 achieved >90% target degradation at the 125mg dose. This data is actually bullish for Foghorn: it validates that SMARCA2 targeting works in humans, and the competitor that generated that proof just walked away. The only remaining SMARCA2 entrant is Amphista Therapeutics (private, UK-based, preclinical molecular glue with Merck, earliest clinic timeline 2027+).

CBP, EP300, ARID1B: Zero competitors identified. Not "one other company at an earlier stage" — zero. No public company, no identifiable private program, no pharma internal pipeline. Academic papers describe CBP/EP300 degrader design in journal articles, but nobody has entered development. ARID1B is considered undruggable by conventional small molecule approaches because it has no enzymatic pocket to target.

Foghorn's Gene Traffic Control platform — built from Cigall Kadoch's Whitehead Institute/MIT research on SWI/SNF complexes — appears to provide structural advantages in making these "undruggable" chromatin targets tractable. The platform was the reason Lilly wrote the $380M check.

Reading Lilly's Actions

Lilly's $300M upfront plus $80M equity investment is the largest of three TPD platform deals they've made (the others: Lycia at $35M upfront/$1.6B potential, Seed at $20M upfront/$780M potential). CEO Dave Ricks mentioned FHD-909 on the Q3 2024 earnings call — a company with an $800B market cap doesn't name-drop a $350M partner's molecule unless the internal organization is paying attention.

The trial design for FHD-909 (NCT06561685) goes well beyond standard dose escalation. It includes randomized dose optimization in NSCLC, expansion into non-NSCLC tumor types, and combination arms with pembrolizumab and pembrolizumab plus platinum doublet chemotherapy. Sites in the US and Japan. The Phase 1b exclusion criterion bars patients with prior SMARCA2 inhibitor/degrader exposure — Lilly is already protecting data integrity for registrational intent.

This is the protocol design of a company planning to advance to Phase 2/3, not one satisfying a contractual obligation.

Counter-signal: Lilly hasn't mentioned Foghorn or FHD-909 on any earnings call since Q3 2024 (seven transcripts searched). This is consistent with a dose-escalation Phase 1 that isn't ready for public data — Lilly has hundreds of pipeline programs and doesn't discuss early-stage trials quarterly. But the silence is noted.

Factor Decomposition

250-day regression shows 79.7% idiosyncratic variance (above the 75% Paleologo target), 16.9% biotech sector (XBI, β=1.07), 4.9% market. Trailing alpha is -12.1% annualized — the stock has been underperforming even on a factor-adjusted basis. This is typical of pre-catalyst clinical biotechs: the market applies a constant discount until data arrives.

The thesis decomposes into six factors. Three where we have informational advantage: the chromatin monopoly (market doesn't distinguish between "one of many TPD companies" and "sole owner of an entire target class"), the pipeline catalyst wave (IND timelines buried in 10-K), and the cash/survival picture (January raise extending runway not yet reflected in the 10-K numbers being digested today). One where edge is moderate: Lilly partnership detail (trial design signaling registrational intent). One where edge is low: FHD-909 clinical outcome (binary, unpredictable). One that's noise: biotech sector exposure.

Edge-driven variance is approximately 60-65% of total — the factors where we have unusual insight account for the majority of the stock's movement. The binary clinical risk (FHD-909 data) is the irreducible uncertainty you size to survive.

What Could Kill This

No TPD drug has ever received FDA approval. The entire modality — PROTACs, molecular glues, selective degraders — remains clinically unproven at the registrational level. Foghorn isn't just a clinical-stage biotech; it's a company building on a frontier with no precedent for approval. This is the foundational risk.

Lilly has unilateral termination rights. Program-by-program or in entirety. Big pharma kills partnerships routinely. The $249.2M in deferred revenue is a sunk cost that doesn't drive decision-making. If FHD-909 Phase 1 data disappoints, Lilly walks and the stock loses its primary validator and cost-sharing partner.

Universal analyst bullishness. All 10 covering analysts are bullish with a mean target of $11.44. When everyone agrees, ask who's left to buy. The contrarian alarm is real.

No insider buying. The CEO gifted 300K shares (tax/estate planning, not conviction signal). Officers sold at $9-10 in September 2024. Nobody on the inside has put cash into shares at current levels. The new CFO (Ryan Maynard, effective February 2026) hasn't had time to buy, but his compensation is options-heavy — $510K base, 400K options. Watch for Form 4 filings.

China CRO/CDMO supply chain. New risk language in the 10-K explicitly flags reliance on China-based contract manufacturers. Given current trade tensions, this could increase costs unpredictably.

Today's -13% is partially unexplained. Factor model explains about 3-4% from the biotech sector selloff (XBI -3%). The remaining ≈9% is idiosyncratic. Probable driver is the Q4 2025 EPS miss (-$0.37 vs -$0.26 estimate) combined with 10-K cash reality ($158.9M vs market expectations). But the magnitude suggests forced selling or a large holder exiting — volume was 2.8x average. This needs resolution before full-sizing.

Forward EV

At $4.92, the stock trades 27% below where BVF Partners, Deerfield Management, and Flagship Pioneering paid to enter in January 2026. Their warrant strikes at $13.42 and $20.13 reveal where sophisticated biotech funds see the upside.

Probability-weighted scenario (18 months):

EV = $8.75 (+78% from current, ≈52% annualized)

After subtracting biotech sector and market factor exposure, applying 60% edge percentage (conservative — company-specific factors only where we have informational advantage):

Forward alpha: ≈25% annualized

This exceeds the Paleologo realistic bound of 5-15% for orthogonal alpha. Either the mispricing is genuine, or our scenarios are too optimistic. Sanity check: institutional biotech specialists paid $6.71 two months ago. Our base case ($8) implies only 19% above their entry — they likely underwrote to $10-15+. Our EV of $8.75 is conservative relative to institutional entry pricing.

Conclusion

The market is pricing FHTX as a single-asset pre-revenue biotech burning cash with uncertain runway. The 10-K reveals something different: a platform company with five active programs across four uncontested chromatin targets, a concrete four-IND catalyst wave beginning in 2026, a Lilly partnership with registrational-intent trial design, and $209M in liquid assets extending runway to H1 2028.

The competitive void is real and verified — zero public or identifiable private competitors on CBP, EP300, or ARID1B targets. The only SMARCA2 competitor just exited the field, leaving Foghorn as the sole clinical-stage program.

The entry setup is attractive: RSI 31.5, stock 27% below smart money entry, near 52-week lows on a day when the biotech sector sold off broadly. The positioning window is now through Q2 2026 — once the first IND files or FHD-909 data drops, the re-rating happens.

The risks are real. No TPD drug has ever been approved. Lilly can walk at any time. The modality could fail. Size for survival, not expected value. But the asymmetry — four first-in-class shots on goal in uncontested targets, funded through the catalyst wave, with the only clinical competitor gone — is not priced at $300M market cap.

Evidence